相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Nathan D. Trinklein et al.
MABS (2019)
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Diego Ellerman
METHODS (2019)
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
Patrick C. Gedeon et al.
CLINICAL CANCER RESEARCH (2018)
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2018)
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Z. Wu et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Zhihao Wu et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
Dionysos Slaga et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Farhad Ravandi et al.
BLOOD (2018)
CD20-Tcb (RG6026), a Novel 2:1 Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial
Martin Hutchings et al.
BLOOD (2018)
A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia
Sayed Shahabuddin Hoseini et al.
BLOOD ADVANCES (2018)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
Andres Lopez-Albaitero et al.
ONCOIMMUNOLOGY (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
Marina Bacac et al.
ONCOIMMUNOLOGY (2016)
Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
Ming Cheng et al.
ONCOIMMUNOLOGY (2016)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
Mahiuddin Ahmed et al.
ONCOIMMUNOLOGY (2015)
Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
Hong Xu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Accumulation of Dynamic Catch Bonds between TCR and Agonist Peptide-MHC Triggers T Cell Signaling
Baoyu Liu et al.
CELL (2014)
Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex
Sarah M. Cheal et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
Aran F. Labrijn et al.
NATURE PROTOCOLS (2014)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets
Maxim Yankelevich et al.
PEDIATRIC BLOOD & CANCER (2012)
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
Nai-Kong V. Cheung et al.
ONCOIMMUNOLOGY (2012)
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens
Gregory L. Moore et al.
MABS (2011)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Multivalent antibodies: when design surpasses evolution
Angel M. Cuesta et al.
TRENDS IN BIOTECHNOLOGY (2010)
The αβ T Cell Receptor Is an Anisotropic Mechanosensor
Sun Taek Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
T Dreier et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
